



EVGENII SAS
Friday, 8 October 2021

ESSENTIAL PHOSPHOLIPIDS (EPLs) – EFFICACY ACROSS THE SPECTRUM OF NAFLD ORIGINS

Presentation key points

- There is currently no standard of care pharmacotherapy for the treatment of NAFLD
- Although currently approved therapeutic approaches rely on treating comorbidities, drug classes such as hepatoprotective agents may improve NAFLD-associated clinical outcomes
- EPLs are a type of hepatoprotective treatment. They assist a number of hepatic functions, such as enhancing metabolism and detoxification in the liver
- Clinical data show that EPL treatment in patients with T2DM and NASH resulted in reduced ALT, AST and γ -GT, and improved steatosis findings from baseline
- Results from RCTs also suggest EPL treatment may reduce liver enzyme levels in patients with ALD and patients with MetS, and improve hepatic echo-texture results in patients with ALD

MAIN TAKEAWAY

Clinical data from RCTs suggest that EPLs can improve outcomes in patients with NAFLD and ALD

ALD, alcoholic liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; EPL, essential phospholipids; MetS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; RCT, randomized controlled trial; T2DM, type 2 diabetes mellitus